Brief: Sorrento Announces Full Enrollment Of Phase I Study Of Intranasal STI-9199
02/05/2022 14:19
May 2 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO ANNOUNCES FULL ENROLLMENT OF PHASE I STUDY OF
INTRANASAL STI-9199 (COVISHIELD™ IN), A POTENT NEUTRALIZATION
ANTIBODY AGAINST OMICRON BA.2 AND ALL VARIANTS OF CONCERN
Source text for Eikon: ID:nGNX2XLw5P
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20